<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35611892</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2190-6009</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of cachexia, sarcopenia and muscle</Title><ISOAbbreviation>J Cachexia Sarcopenia Muscle</ISOAbbreviation></Journal><ArticleTitle>The p97-Nploc4 ATPase complex plays a role in muscle atrophy during cancer and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2225</StartPage><EndPage>2241</EndPage><MedlinePgn>2225-2241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jcsm.13011</ELocationID><Abstract><AbstractText Label="BACKGROUND">The p97 complex participates in the degradation of muscle proteins during atrophy upon fasting or denervation interacting with different protein adaptors. We investigated whether and how it might also be involved in muscle wasting in cancer, where loss of appetite occurs, or amyotrophic lateral sclerosis (ALS), where motoneuron death causes muscle denervation and fatal paralysis.</AbstractText><AbstractText Label="METHODS">As cancer cachexia models, we used mice bearing colon adenocarcinoma C26, human renal carcinoma RXF393, or Lewis lung carcinoma, with breast cancer 4T1-injected mice as controls. As ALS models, we employed 129/SvHsd mice carrying the mutation G93A in human SOD1. The expression of p97 and its adaptors was analysed in their muscles by quantitative real-time polymerase chain reaction (qPCR) and western blot. We electroporated plasmids into muscles or treated mice with disulfiram (DSF) to test the effects of inhibiting p97 and nuclear protein localization protein 4 (Nploc4), one of its adaptors, on atrophy.</AbstractText><AbstractText Label="RESULTS">The mRNA levels of p97 were induced by 1.5-fold to 2-fold in tibialis anterior (TA) of all the cachectic models but not in the non-cachectic 4T1 tumour-bearing mice (P&#xa0;&#x2264;&#xa0;0.05). Similarly, p97 was high both in mRNA and protein in TA from 17-week-old SOD1<sup>G93A</sup> mice (P&#xa0;&#x2264;&#xa0;0.01). Electroporation of a shRNA for murine p97 into mouse muscle reduced the fibre atrophy caused by C26 (P&#xa0;=&#xa0;0.0003) or ALS (P&#xa0;&#x2264;&#xa0;0.01). When we interrogated a microarray, we had previously generated for the expression of p97 adaptors, we found Derl1, Herpud1, Nploc4, Rnf31, and Hsp90ab1 induced in cachectic TA from C26-mice (Fold change&#xa0;&gt;&#xa0;1.2, adjusted P&#xa0;&#x2264;&#xa0;0.05). By qPCR, we validated their inductions in TA of cachectic and ALS models and selected Nploc4 as the one also induced at the protein level by 1.5-fold (P&#xa0;&#x2264;&#xa0;0.01). Electroporation of a CRISPR/Cas9 vector against Nploc4 into muscle reduced the fibre atrophy caused by C26 (P&#xa0;=&#xa0;0.01) or ALS (P&#xa0;&#x2264;&#xa0;0.0001). Because DSF uncouples p97 from Nploc4, we treated atrophying myotubes with DSF, and found accumulated mono and polyubiquitinated proteins and reduced degradation of long-lived proteins by 35% (P&#xa0;&#x2264;&#xa0;0.0001), including actin (P&#xa0;&#x2264;&#xa0;0.05). DSF halves Nploc4 in the soluble muscle fraction (P&#xa0;&#x2264;&#xa0;0.001) and given to C26-bearing mice limited the body and muscle weight loss (P&#xa0;&#x2264;&#xa0;0.05), with no effect on tumour growth.</AbstractText><AbstractText Label="CONCLUSIONS">Overall, cancer cachexia and ALS seem to display similar mechanisms of muscle wasting at least at the catabolic level. The p97-Nploc4 complex appears to have a crucial role in muscle atrophy during these disorders and disrupting this complex might serve as a novel drug strategy.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley &amp; Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Re Cecconi</LastName><ForeName>Andrea David</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barone</LastName><ForeName>Mara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaspari</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortarolo</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porcu</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Oncology, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terribile</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccirillo</LastName><ForeName>Rosanna</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1613-9352</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Fondazione Italiana di ricerca per la SLA - Sclerosi Laterale Amiotrofica (AriSLA)</Agency><Country/></Grant><Grant><GrantID>19927</GrantID><Agency>Associazione Italiana per la Ricerca sul Cancro</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Cachexia Sarcopenia Muscle</MedlineTA><NlmUniqueID>101552883</NlmUniqueID><ISSNLinking>2190-5991</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C415829">Herpud1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000251" MajorTopicYN="Y">Adenosine Triphosphatases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002100" MajorTopicYN="N">Cachexia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="Y">Muscular Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="Y">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cancer cachexia</Keyword><Keyword MajorTopicYN="N">Muscle wasting</Keyword><Keyword MajorTopicYN="N">Nploc4</Keyword><Keyword MajorTopicYN="N">Protein degradation</Keyword><Keyword MajorTopicYN="N">p97-VCP complex</Keyword></KeywordList><CoiStatement>All authors declare they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35611892</ArticleId><ArticleId IdType="pmc">PMC9397562</ArticleId><ArticleId IdType="doi">10.1002/jcsm.13011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bodnar N, Rapoport T. Toward an understanding of the Cdc48/p97 ATPase. F1000Research 2017;6:1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543420</ArticleId><ArticleId IdType="pubmed">28815021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramadan K, Bruderer R, Spiga FM, Popp O, Baur T, Gotta M, et al. Cdc48/p97 promotes reformation of the nucleus by extracting the kinase Aurora B from chromatin. Nature 2007;450:1258&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097415</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccirillo R, Goldberg AL. The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO J 2012;31:3334&#x2013;3350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411080</ArticleId><ArticleId IdType="pubmed">22773186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Meyer HH, Rapoport TA. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 2001;414:652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718385</ArticleId></ArticleIdList></Reference><Reference><Citation>Volodin A, Kosti I, Goldberg AL, Cohen S. Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc Natl Acad Sci U S A 2017;114:E1375&#x2013;E1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338431</ArticleId><ArticleId IdType="pubmed">28096335</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GDJ, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin&#x2010;containing protein. Nat Genet 2004;36:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, Abramzon Y, van Deerlin V, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010;68:857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimonis VE, Fulchiero E, Vesa J, Watts G. VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta 2008;1782:744&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">18845250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentsch S, Rumpf S. Cdc48 (p97): a &#x2018;molecular gearbox&#x2019; in the ubiquitin pathway? Trends Biochem Sci 2007;32:6&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17142044</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer HH, Shorter JG, Seemann J, Pappin D, Warren G. A complex of mammalian ufd1 and npl4 links the AAA&#x2010;ATPase, p97, to ubiquitin and nuclear transport pathways. EMBO J 2000;19:2181&#x2013;2192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384367</ArticleId><ArticleId IdType="pubmed">10811609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokireddy S, Wijesoma IW, Sze SK, McFarlane C, Kambadur R, Sharma M. Identification of atrogin&#x2010;1&#x2010;targeted proteins during the myostatin&#x2010;induced skeletal muscle wasting. Am J Physiol Cell Physiol 2012;303:C512&#x2013;C529.</Citation><ArticleIdList><ArticleId IdType="pubmed">22673621</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679633</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger B, Vergani L, Soraru G, Hespel P, Derave W, Gobelet C, et al. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin&#x2010;1. FASEB J 2006;20(3):583&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507768</ArticleId></ArticleIdList></Reference><Reference><Citation>Houten L, Reilley AA. An investigation of the cause of death from cancer. J Surg Oncol 1980;13:111&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">7359917</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc 2018;93:1617&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Zecca C, Piccininni M, Benmahamed S, Dell'Abate MT, Barulli MR, et al. Plasma inflammatory cytokines are elevated in ALS. Front Neurol 2020;11:552295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691268</ArticleId><ArticleId IdType="pubmed">33281700</ArticleId></ArticleIdList></Reference><Reference><Citation>Argil&#xe9;s JM, Busquets S, Toledo M, L&#xf3;pez&#x2010;Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009;3:263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">19713854</ArticleId></ArticleIdList></Reference><Reference><Citation>Huot JR, Pin F, Bonetto A. Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity. Am J Cancer Res 2021;11:2990&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8263661</ArticleId><ArticleId IdType="pubmed">34249440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartori R, Hagg A, Zampieri S, Armani A, Winbanks CE, Viana LR, et al. Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci Transl Med 2021;13:eaay9592.</Citation><ArticleIdList><ArticleId IdType="pubmed">34349036</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller JMM, Deinhardt K, Rosewell I, Warren G, Shima DT. Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochem Biophys Res Commun 2007;354:459&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239345</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, et al. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF&#x2010;1 activation in muscle. Oncotarget 2015;6:3043&#x2013;3054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413636</ArticleId><ArticleId IdType="pubmed">25460504</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, Tortarolo M, Vallarola A, Freschi M, Pasetto L, et al. New insights on the mechanisms of disease course variability in ALS from mutant SOD1 mouse models. Brain Pathol 2016;26:237&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029191</ArticleId><ArticleId IdType="pubmed">26780365</ArticleId></ArticleIdList></Reference><Reference><Citation>Re Cecconi AD, Forti M, Chiappa M, Zhu Z, Zingman LV, Cervo L, et al. Musclin, a myokine induced by aerobic exercise, retards muscle atrophy during cancer cachexia in mice. Cancer 2019;11:1541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6826436</ArticleId><ArticleId IdType="pubmed">31614775</ArticleId></ArticleIdList></Reference><Reference><Citation>Majera D, Skrott Z, Chroma K, Merchut&#x2010;Maya JM, Mistrik M, Bartek J. Targeting the NPL4 adaptor of p97/VCP segregase by disulfiram as an emerging cancer vulnerability evokes replication stress and DNA damage while silencing the ATR pathway. Cell 2020;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7072750</ArticleId><ArticleId IdType="pubmed">32085572</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, et al. Alcohol&#x2010;abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 2017;552:194&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5730499</ArticleId><ArticleId IdType="pubmed">29211715</ArticleId></ArticleIdList></Reference><Reference><Citation>Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, McAnally J, et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 2010;143:35&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982779</ArticleId><ArticleId IdType="pubmed">20887891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ham DJ, B&#xf6;rsch A, Lin S, Th&#xfc;rkauf M, Weihrauch M, Reinhard JR, et al. The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia. Nat Commun 2020;11:4510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481251</ArticleId><ArticleId IdType="pubmed">32908143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin&#x2010;proteasome pathway in normal and disease states. J Am Soc Nephrol JASN 2006;17:1807&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">16738015</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JL, Lawrence MM, Ahn B, Kneis P, Piekarz KM, Qaisar R, et al. Cancer cachexia in a mouse model of oxidative stress. J Cachexia Sarcopenia Muscle 2020;11:1688&#x2013;1704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749559</ArticleId><ArticleId IdType="pubmed">32918528</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, Lautenschl&#xe4;ger J, Weidemann L, Ruhmer J, Witte OW, Grosskreutz J. Endoplasmic reticulum stress is accompanied by activation of NF&#x2010;&#x3ba;B in amyotrophic lateral sclerosis. J Neuroimmunol 2014;270:29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">24666819</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Kumar A. ER stress and unfolded protein response in cancer cachexia. Cancer 2019;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6966641</ArticleId><ArticleId IdType="pubmed">31817027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacheck JM, Hyatt J&#x2010;PK, Raffaello A, Thomas Jagoe R, Roy RR, Reggie Edgerton V, et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 2007;21:140&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116744</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitanio D, Vasso M, Ratti A, Grignaschi G, Volta M, Moriggi M, et al. Molecular signatures of amyotrophic lateral sclerosis disease progression in hind and forelimb muscles of an SOD1(G93A) mouse model. Antioxid Redox Signal 2012;17:1333&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437050</ArticleId><ArticleId IdType="pubmed">22563797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma JF, Sanchez BJ, Hall DT, Tremblay A&#x2010;MK, Di Marco S, Gallouzi I&#x2010;E. STAT3 promotes IFN&#x3b3;/TNF&#x3b1;&#x2010;induced muscle wasting in an NF&#x2010;&#x3ba;B&#x2010;dependent and IL&#x2010;6&#x2010;independent manner. EMBO Mol Med 2017;9:622&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412921</ArticleId><ArticleId IdType="pubmed">28264935</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J&#x2010;M, Wu H, Zhang W, Blackburn MR, Jin J. The p97&#x2010;UFD1L&#x2010;NPL4 protein complex mediates cytokine&#x2010;induced I&#x3ba;B&#x3b1; proteolysis. Mol Cell Biol 2014;34:335&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911508</ArticleId><ArticleId IdType="pubmed">24248593</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan M, Zheng Q, Yu Y, Ai H, Xie Y, Zeng X, et al. Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative. Nat Commun 2021;12:121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785736</ArticleId><ArticleId IdType="pubmed">33402676</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BR, Lim NKH, McAllum EJ, Donnelly PS, Hare DJ, Doble PA, et al. Oral treatment with Cu (II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2014;34:8021&#x2013;8031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608261</ArticleId><ArticleId IdType="pubmed">24899723</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JR, Trias E, Beilby PR, Lopez NI, Labut EM, Bradford CS, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co&#x2010;expressing the Copper&#x2010;Chaperone&#x2010;for&#x2010;SOD. Neurobiol Dis 2016;89:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4785045</ArticleId><ArticleId IdType="pubmed">26826269</ArticleId></ArticleIdList></Reference><Reference><Citation>von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. J Cachexia Sarcopenia Muscle 2021;12:2259&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8718061</ArticleId><ArticleId IdType="pubmed">34904399</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>